Tatiana Lushchaeva

Ms. Tatiana Lushchaeva

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in Diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
VSV. P. Sokurenko
V. P. Sokurenko
AKA. V. Karpenko
A. V. Karpenko
TLTatiana Lushchaeva
Tatiana Lushchaeva
TPT. E. Ponezha
T. E. Ponezha
INTRODUCTION: Effect of adiuvant radiation therapy (RT) on oncologic outcomes is well-known and confirmed by different trials. Optimal time to start RT is 6–8 weeks after surgery. Increasing duration of RT delay beyond that interval leads to decrease in overall survival (OS) and makes loco-regional recurrence (LRC) more probable. However, more than 50% patients do not receive adjuvant treatment in time (Mitra S. et al., 2022). Overall treatment time (77–100 days) is another factor that influences effectiveness of adjuvant RT. In order to keep within that time limits non-conventional regimens of RT can be used.OBJECTIVE: To test safety and feasibility of hypofractionated adjuvant RT in patients with locally advanced squamous cell carcinoma of oral cavity and oropharynx.MATERIALS AND METHODS: Patients with stage III–IV squamous cell carcinoma of oral cavity and oropharynx (n=11) who underwent surgery and have to recieve adjuvant RT in 8 weeks and more after surgery are included. Dose was delivered using Volumetric Modulated Arc Therapy (VMAT) and simultaneous integrated boost.RESULTS: Patients (n=11) completed RT successfully. Surgery-to-RT interval ranges between 9 and 15 weeks. Dose per fraction on high-risk-CTV varies between 2,5 and 2,75 Gy. Acute side-effects (oral mucositis grade II) presented after 27–32 Gy (11–13 fractions) in 9 patient out of 11 and reached maximum (oral mucositis grade III, radiation dermatitis grade II) at the end of the treatment.CONCLUSIONS: Hypofractionated adjuvant RT (VMAT) can be safely used in patients with locally advanced squamous cell carcinoma of oral cavity and oropharynx and local acute toxicity can be controlled.

16 March 2022 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
JVJ. N. Vinogradova
J. N. Vinogradova
МKМ. М. Khodzhibekova
М. М. Khodzhibekova
VRV. V. Ryabchikova
V. V. Ryabchikova
TLTatiana Lushchaeva
Tatiana Lushchaeva
NIN. V. Ilyin
N. V. Ilyin
Introduction: Gastric extranodal diffuse large B-cell lymphoma (DLBCL) is one of the most common types of lymphoma. The management of patients with DLBCL of s tomach includes immunochemotherapy, radiotherapy and surgery, but there is no standard approach. Endoscopy as a part of diagnostic workup is obligatory, but using positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) is not obligatory at different stages of observation and treatment.Purpose: To evaluate the diagnostic precision of PET/CT with 18F-FDG in both assesement and treatment stages for patients with extranodal DLBCL of stomach. Materials and methods. In this study we describe early and late therapeutic outcomes of 23 patients with primary extranodal DLBCL of stomach, treated in our center between 2010 and 2018, who received R-CHOP immunochemotherapy regimen. There were PET/CT and fibrogastroduodenoscopy (EGD) provided for all patients on every stage of assessment.Results: The diagnostic accuracy of PET/CT before the treatment was 87 %, after immunochemotherapy — 91,3 %, after radiotherapy — 100 %.Conclusions: This study shows up the role of including PET/CT scan as an observation method for patients with extranodal DLBCL of stomach on each stage of treatment and response assessment, especially for long-term prognosis evaluation.

2 June 2026 in Radiation
Verified
Journal Article
Open access
PDF file
DMDusan Milanovic
Dusan Milanovic
TLTatiana Lushchaeva
Tatiana Lushchaeva
HHHai Minh Ha
Hai Minh Ha
RCRaul-Ciprian Covrig
Raul-Ciprian Covrig
CSChristian Scheller
Christian Scheller
DMDaniel Medenwald
Daniel Medenwald
Preclinical studies and data from other cancers suggest that inhibition of the Hedgehog (Hh) pathway also has antiproliferative effects on glioma cells. A key component of this pathway is the Smoothened (SMO) protein, which is expressed in high-grade gliomas. Itraconazole (ITRA), a widely used antifungal agent, inhibits SMO, the PI3K/AKT/mTOR pathway, and the VEGF/VEGFR-2 axis—both of which are critical for GBM progression and angiogenesis. This protocol describes a prospective, single-center, dose-escalation phase I study with the classical 3 + 3 design in order to determine the MTD of ITRA. The study enrolls patients with a newly histologically confirmed diagnosis of GBM, without previous treatment except surgery. They will be treated with standard RT schedule (60 Gy in 30 fractions) with concurrent TMZ 75 mg/m2 and ITRA 2 × 100 mg, 200 mg, or 300 mg daily. The primary endpoint is to determine the MTD of ITRA given concurrently with RT + TMZ. Secondary endpoints include safety and tolerability of ITRA, overall survival (OS), progression-free survival (PFS), overall objective response rate, use of corticosteroids, treatment compliance, and health-related quality of life (EORTC QLQ-C30 and BN20). Participants will be monitored for one week post-treatment. All relevant statistics will be primarily descriptive.